Research programme: siRNA therapeutics - AstraZeneca/Silence Therapeutics

Drug Profile

Research programme: siRNA therapeutics - AstraZeneca/Silence Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Silence Therapeutics
  • Developer AstraZeneca; Silence Therapeutics
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Respiratory tract disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in United Kingdom
  • 21 Mar 2012 Preclinical development is ongoing
  • 21 Apr 2010 Silence Therapeutics and AstraZeneca have extended their collaborative agreement for the development of delivery approaches for siRNA therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top